Bulevirtide and HBV RNA Inhibitors for HDV Co-Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis D virus (HDV) infection are inadequate, particularly in the context of co-infection with hepatitis B virus (HBV), as they fail to effectively target and inhibit key viral proteins and processes essential for HDV replication and spread.
Innovation Solution
A combination therapy using bulevirtide, a hydrophobic modified preS-derived peptide of HBV, and inhibitory nucleic acids targeting HBV proteins such as HBc, HBx, or HBsAg, to disrupt viral entry and replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for HDV infection are used, then treatment simplicity is maintained, but antiviral effectiveness is insufficient
Solution Approach 1:
The patent combines bulevirtide (a preS1-derived peptide) with inhibitory nucleic acids targeting HBV proteins (HBc, HBx, or HBsAg) to create a combination therapy. This merging of two different antiviral mechanisms targets multiple viral proteins simultaneously, achieving superior antiviral effectiveness compared to single-agent treatments while managing treatment complexity through a coordinated two-component regimen.
2Adaptability or versatility
If single-agent therapy is used, then treatment simplicity is maintained, but ability to target multiple viral proteins is reduced
Solution Approach 1:
The combination therapy achieves multi-functionality by simultaneously targeting multiple HBV proteins (preS1 via bulevirtide, plus HBc, HBx, or HBsAg via inhibitory nucleic acids). This universal approach allows a single therapy regimen to disrupt multiple viral replication processes and envelope protein functions, enhancing adaptability against the virus while maintaining a manageable therapy structure.
3Reliability
If combination therapy with bulevirtide and inhibitory nucleic acids is used, then antiviral effectiveness is improved, but manufacturing and administration complexity increases
Solution Approach 1:
The therapy is segmented into two distinct components: bulevirtide (a peptide drug) and inhibitory nucleic acids (siRNA or ASO). This segmentation allows each component to be manufactured and characterized independently, then combined in a coordinated formulation. The peptide and nucleic acid can be produced using established pathways, and their combination can be stabilized through appropriate excipients and packaging, managing manufacturing complexity while achieving enhanced antiviral effectiveness.
Data Source
AI summary
The present application provides combinations of bulevirtide, or a pharmaceutically acceptable salt thereof, and an inhibitory nucleic acid targeting hepatitis B virus (HBV), useful for treating hepatitis D virus (HDV) infection.